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RivaroxabanAbstract Rivaroxaban (RIVA), an amide group-containing oral anticoagulant was subjected to
stress conditions commonly required for the registration of pharmaceuticals: base and acid-catalyzed
hydrolysis (0.1 M, 60 C, 3–6 h), oxidation (10%H2O2, 24 h), photodegradation (300–800 nm, 24 h)
and thermal decomposition (50 C, 6 h). Two major degradation products were separated and iden-
tiﬁed using TLC and LC/MS/MS, respectively. An orthogonal stability-indicating testing protocol
(RP-HPLC and NP-TLC-densitometry) was developed and validated according to ICH guidelines.
Both assays enabled the determination of RIVA in the presence of its degradation products as well as
the kinetics of degradation. Determination was carried out over a concentration range of
(5.00–50.00 lg/mL) and (0.40–12.00 lg/band) with an accuracy of (100.81%± 1.03) and
(100.29%± 1.08) for HPLC and TLC-densitometry, respectively. Results indicated that RIVA
was stable towards oxidation, photodegradation and thermal decomposition but extremely sensitive
to hydrolysis. Two major degradation products were detected in the case of base-catalyzed hydroly-
sis while only one degradation product was detected upon acid-catalyzed hydrolysis. This could be
attributed to the presence of amide groups in RIVA structure of different stability proﬁles. The kinet-
ics of hydrolysis was investigated in more detail and the reaction was found to follow the pseudo ﬁrst
order kinetics, as conﬁrmed by the results of both HPLC and TLC-densitometric assays. The appli-
cability of the assay for the determination of RIVA content and dissolution pattern of the innovator
product as well as three generic formulations was demonstrated.
ª 2015 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
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Rivaroxaban (RIVA) is the ﬁrst orally active direct factor Xa
inhibitor; a coagulation factor in the blood coagulation path-
way leading to thrombin generation and clot formation.1,2
RIVA is well absorbed from the gut and exerts maximum inhi-
bition of factor Xa within four hours after administration. Its
effect lasts 8–12 h, however factor Xa activity does not return
to normal until 24 h. Currently, there is no speciﬁc way to
reverse the anticoagulant effect of RIVA in the case of major
bleeding.3,4 Chemically, RIVA is (S)-5-chloro-N-thiophene-2-
carboxamide (Fig. 1).2 It is a white, crystalline powder that
is freely to very soluble in DMF, acetonitrile, chloroform
and practically insoluble in water.2 Only few methods of anal-
ysis have been reported for RIVA in its dosage forms using the
following techniques: spectrophotometry,5–7 TLC-densitome-
try5,8 and HPLC.5,9–14 However, proper method validation
to pharmaceutical industry standards has not been reported.
A sensitive and speciﬁc bioanalytical assay has also been
reported for assessment of the pharmacokinetics of RIVA
using LC/MS/MS in human.15
The stability proﬁle of RIVA under various stress condi-
tions has been recently investigated by the same authors but
in several reports. Degradation products were detected upon
incubation for RIVA for three consecutive days under the
effect of acid- and base-catalyzed hydrolysis, photo and ther-
mal degradation.10,12,13 However, these degradation products
were neither isolated nor identiﬁed. Recently, a systematic
investigation of the stability of RIVA under various stress con-
ditions has been reported.16 In this study, RP-HPLC along
with tandem mass spectrometry and NMR have been used
to reveal the identity of the degradation products. Acid and
base-catalyzed hydrolysis reactions were investigated using
1.0 N hydrochloric acid and sodium hydroxide, respectively
and three hydrolytic degradation products were detected.
However, the authors revealed the identity of only two of
the three degradation products and did not investigate the
kinetics of degradation.16 It should be noted that two degrada-
tion products of different chemical structures and molecular
weights were previously identiﬁed upon treatment of RIVA
with 2.0 M sodium hydroxide.5 Such contradicting results con-
ﬁrmed the need for a thorough investigation of the degrada-
tion mechanism of RIVA.
Investigation of the stability of drugs represents an impor-
tant issue in drug quality evaluation. Stress testing of drug sub-
stance can help to identify the likely degradation products and
to provide important information on drug’s inherent stability.
Consecutively, it can be a fundamental contribution to develop
and validate stability indicating analytical methods used in
monitoring of quality of pharmaceutical products.17–19 Inde-
pendent of the ﬁnal dosage form, forced drug degradation byFigure 1 Chemical structure of Rivaroxaban.exposure of drug solution to acid or alkaline conditions is use-
ful to predict the potential hydrolytic degradation products.
Hydrolysis is one of the most common degradation chemical
reactions. Since water, either as a solvent or in the form of
the potential moisture in the air, contacts most pharmaceutical
formulations to some degree; the potential for this degradation
pathway exists for most drugs and excipients.20,21
ICH guideline for stability testing of new drug sub-
stances22–24 requires that stress degradation studies should be
carried out. However, no single set of stress conditions was rec-
ommended by ICH guidelines. For active pharmaceutical
ingredients containing labile functional groups such as RIVA
(Fig. 1), a wide range of possibilities for the degradation prod-
ucts exist. Mild stress conditions should be trialed in order to
induce the formation of degradation products that could be
obtained under the environmental conditions encountered dur-
ing handling and storage.21,25 It should be highlighted also that
relying on a single separation technique might lead to inappro-
priate interpretation of degradation pathway. The degradation
proﬁle of RIVA has been previously investigated by our
research group.26 In this work, the effect of various stress
factors on the stability of RIVA was thoroughly investigated.
LC/MS/MS was used to identify the major degradation products
of the studied drug under various stress conditions. An orthog-
onal analysis protocol; RP-HPLC and NP-TLC-densitometry
was developed and validated to pharmaceutical industry stan-
dards in order to determine the intact drug in the presence of
all degradation products. The kinetics of degradation using
both assays has also been investigated in order to cross-vali-
date the obtained results. Results were compared to the previ-
ously reported patterns for degradation for RIVA that
revealed different degradation products. The applicability of
the assay protocol to routine quality control testing and pre-
formulation studies for a new generic product has also been
investigated in comparison to the innovator product.
2. Experimental
2.1. Materials and samples
RIVA reference standard, raw material and tablet formula-
tions developed during preformulation studies (10 mg/tablet)
were kindly supplied by Sigma Pharmaceutical Industries
(Egypt). The innovator product Xarelto tablet, 10 mg/tablet
(Bayer Schering Pharma, Germany) was obtained from the
market. All other chemicals and solvents were of HPLC grade
and were obtained from Sigma (Germany). A stock solution of
RIVA (1.00 mg/mL) was prepared in acetonitrile and was used
to prepare the RIVA standard series as well as samples for the
stability studies.
2.2. Instrumentation
A Shimadzu LC prominence system (Shimadzu, Japan)
equipped with a diode array detector (DAD) was used. System
control and data analysis were carried out using LabSolutions
CS (Schimadzu, Japan). An ofﬂine automatic sample applica-
tor equipped with 100 lL syringe (Camag Linomat 5, Switzer-
land) and plate scanner (Camag, Switzerland) was employed
for the TLC-densitometric analysis. Both of the applicator
and the densitometer were controlled using winCATS software
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ucts was carried out using LC/MS/MS in positive ionization
mode (Agilent technologies, USA). Hardware control as well
as data acquisition and treatment were carried out using Mass
Hunter software, (Agilent technologies, Germany). The col-
umn used was Inertsil C18, 5 lm (4.60 · 50.00 mm) and the
mobile phase was 10 mM ammonium formate: acetonitrile
(30:70 v/v). Thermal stability studies were performed in a
dry air oven (Normschliff Gera¨tebau, Germany). Photostabil-
ity study was carried out using a Suntest CPS+ cabinet (Atlas,
Germany), 1.2 x 106 Lux.h. Dissolution experiments were car-
ried out using Vision Classic Dissolution Tester (Hanson,
USA). Ultra-pure water was obtained using an ELGA water
puriﬁcation system (Bucks, UK). Chemical structures and cal-
culation of molecular weight were achieved using ChemDarw
Ultra v.8.0, 2003 (CambridgeSoft Corporation, USA).
2.3. HPLC Assay
2.3.1. Optimization and system suitability
Chromatographic separations were carried out using a
Thermo C18 column, 150 · 4 mm, 5 lm (Germany). RVA
degraded samples were prepared as described under ‘‘2.5 Sta-
bility Study’’ and used for optimization of the HPLC assay.
Separation was achieved using 50 mM phosphate buffer (pH
3.0): acetonitrile (70:30 v/v) using isocratic elution at
1.00 mL/ min. Detection was carried out at 249 nm and the
spectral purity of all detected peaks has been investigated. Sys-
tem suitability criteria were calculated27 in order to assess the
efﬁciency of separation.
2.3.2. Calibration and validation
Calibration curve was constructed using a standard series cov-
ering a concentration range (5.00–50.00 lg/mL). The obtained
regression equation was used to calculate the concentration of
RIVA throughout the stability study. Assay validation was
carried out according to ICH guidelines28 and the following
parameters were determined: speciﬁcity, linearity, range, accu-
racy, precision, LOD, and LOQ.
2.4. TLC-densitometric assay
2.4.1. Optimization and system suitability
Pre-coated TLC-plates, silica gel 60 F254 (20 · 20 cm,
0.25 mm), E. Merck (Germany) were used for all determina-
tions. Similar to the HPLC assay, optimization of the TLC-
densitometric assay was achieved using RIVA degraded sam-
ples. In all experiments, bands were spaced 2.0 cm apart and
1.5 cm from the bottom edge of the plate.29 A mobile phase
composed of chloroform: methanol: glacial acetic acid
(100:5:2, v/v/v) was used and detection was carried out at
249 nm. System suitability criteria were determined27 in order
to assess the efﬁciency of separation.
2.4.2. Calibration and validation
Calibration curve was constructed using a standard series cov-
ering a concentration range 0.40–12.00 lg/band. Analysis was
carried out as described and the integrated peak area was plot-
ted versus concentration of RIVA and the regression equationwas calculated. Assay validation was carried out according to
ICH guidelines.28
2.5. Stability study
A set of RIVA standard solutions (50.00 lg/mL) was subjected
to mild stress conditions recommended by ICH guidelines.23,24
Degradation products were initially resolved using TLC, as
described. Bands corresponding to degradation products were
carefully excised from the plates and extracted using acetoni-
trile. The identity and purity of separated bands were revealed
using LC/MS/MS. Degraded samples were used to optimize
and verify the resolution of the HPLC and TLC-densitometric
assays. Extracted degradation products were also analyzed
using HPLC and TLC-densitometric assays in order to reveal
their elution pattern. The kinetics of hydrolysis was then inves-
tigated in detail.
2.5.1. Base and acid-catalyzed hydrolysis
Suitable aliquots of RIVA stock solution were accurately
transferred into a set of 25 mL volumetric ﬂasks. The volume
was completed to the mark using either 0.1 M sodium hydrox-
ide or 0.1 M hydrochloric acid so that the ﬁnal concentration
of RIVA was 50.00 lg/mL. The hydrolytic degradation of
RIVA was investigated after incubation at 60 C for 3 h. At
the end of the incubation period, the solutions were accurately
transferred into 25 mL volumetric ﬂasks and completed to vol-
ume using acetonitrile. Samples were then subjected to HPLC
and TLC-densitometric analyses in order to reveal possible
degradation products.
2.5.2. Oxidative degradation
Suitable aliquots of RIVA stock solution were accurately
transferred into a set of 25 mL volumetric ﬂasks and 3 mL
of 10% H2O2 solution were added. Samples were incubated
at room temperature away from light for 24 h and then the vol-
ume was completed using acetonitrile to a ﬁnal concentration
of 50.00 lg/mL. Possible oxidative degradation products were
then investigated using HPLC and TLC-densitometric assays.
2.5.3. Photodegradation
Aliquots equivalent to 25 mL of RIVA (50.00 lg/mL) were
placed as a thin layer in a set of petri dishes. Samples were
incubated in a temperature-controlled photostability cabinet
for a period of 24 h. Irradiated samples were quantitatively
transferred and completed to volume using acetonitrile to a
ﬁnal concentration of 50.00 lg/mL and the analysis protocol
was then carried out.
2.5.4. Thermal decomposition
In order to investigate the thermal stability of RIVA in solid
state, aliquots of 25 mg of RIVA powder were weighed into
a set of 5 mL vials. Samples were incubated in a dry air over
at 50 C, RH= 0% for 6 h. At the end of the incubation per-
iod, vials were left to cool down to room temperature and the
powder was dissolved in acetonitrile to a ﬁnal concentration of
50.00 lg/mL. Possible degradation at the studied experimental
conditions was then investigated using the proposed analysis
protocol.
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Aliquots of RIVA stock solution were diluted using either
0.1 M sodium hydroxide or 0.1 M hydrochloric acid to a ﬁnal
concentration of 50.00 lg/mL. Samples were incubated in
sealed glass vials at 60 C and every 15 min the content of
one vial was analyzed using both assays. The decrease in RIVA
concentration was monitored over the incubation period in
order to investigate various kinetics parameters of the hydroly-
sis reaction.
2.6. Applications
2.6.1. Application to pharmaceutical formulations
A total of ten Xarleto tablets (Innovator product) were accu-
rately weighed and crushed to a ﬁne powder. An amount
equivalent to one tablet (10 mg RIVA) was extracted using
70 mL of acetonitrile by sonication for 10 min. The mixture
was transferred into a 100 mL volumetric ﬂask through a
Whatman No. 1 ﬁlter paper. The residue was washed twice
using acetonitrile and the combined ﬁltrate and washings were
made up to the mark with acetonitrile. A suitably diluted sam-
ple (50.00 lg/mL) was ﬁltered using 0.45 lm membrane ﬁlter
then analyzed using the developed analysis protocol as well
as the reported method.12
2.6.2. Application to preformulation studies
In vitro drug release study was carried out according to disso-
lution procedures recommended for conventional single-entity
tablet formulations.30,31 Three different RIVA formulas (E001,
E002 and E003) were prepared using different amounts of
sodium lauryl sulfate (0.5, 1.0 and 1.5 mg). The dissolution
pattern was then investigated in comparison to the innovator
product using 900 mL dissolution medium (acetate buffer,
pH 4.5 containing 0.4% SDS) at 37 C and stirring rate
75 rpm for 45 min. Samples were withdrawn at regular time
intervals and analysis was carried out using the HPLC assay.
3. Results and discussion
In this study, RIVA was exposed to base- and acid-catalyzed
hydrolysis, oxidation, photodegradation and thermal decom-
position as described. Initially, TLC analysis was carried out
and all detectable bands were scratched and extracted using
acetonitrile. Tandem mass spectrometry was employed in
order to reveal the identity of major degradation products.
Results revealed two bands corresponding to the major degra-
dation products; D1, m/z 454 and D2, m/z 410 (Fig. S1a and
S1b). The proposed structures of D1 and D2 were determined
based on their m/z and the possible degradation pathways for
RIVA (Fig. S2). Two simple and sensitive stability-indicating
assays were developed and validated to pharmaceutical indus-
try standards in order to determine the inherent stability char-
acteristics of RIVA. Extracted degradation products were
further analyzed using both assays in order to reveal their elu-
tion pattern and purity. The developed stability-indicating
analysis protocol was employed for regular quality control
testing and while developing RIVA generic formulations.
Results were compared to those obtained upon the analysis
of the innovator product.3.1. HPLC assay
3.1.1. Optimization and system suitability
Initially, several previously reported separation conditions
were tried; acetonitrile: water (55:45 v/v)11 and acetonitrile:
methanol (50:50 v/v).12 However, no satisfactory resolution
of the intact drug from its degradation products was obtained
(results not shown). Optimum resolution was obtained upon
using 50 mM phosphate buffer (pH 3.0): acetonitrile (70:30
v/v) as the mobile phase at 1.00 mL/min. Fig. 2 shows the anal-
ysis results of the degraded samples in comparison to an equiv-
alent standard RIVA solution. Results indicated that two
major degradation products were formed after base-catalyzed
hydrolysis; D1 and D2 at tR 5.8 and 2.8 min, respectively
(Fig. 2C). On the other hand, only one major degradate; D2
at tR 2.8 min was obtained under acid-catalyzed hydrolysis
conditions (Fig. 2B). The order of elution of the degradation
products was conﬁrmed via analysis of the previously sepa-
rated and extracted major degradates from TLC plates as
described above. The spectral purity of RIVA, D1 and D2
peaks were investigated using DAD in order to verify our
understanding for the proposed degradation mechanism
(Fig. S3). System suitability parameters were calculated
according to USP guidelines27 in order to verify the separation
efﬁciency (Table 1).
3.1.2. Calibration and validation
A standard series of RIVA was prepared and analyzed as
described above. Linear relationship was obtained between
the integrated peak area and RIVA concentration over a range
of 5.00–50.00 lg/mL. These results conﬁrmed that the devel-
oped RP-HPLC assay is more superior to the previously
reported method of Ramisetti et al. with respect to sensitivity
and linearity range that was 50.00–150.00 lg/mL.16 Regression
equation and validation parameters were summarized in
Table 2. The speciﬁcity of the assay was demonstrated through
the ability of the assay to determine RIVA in the presence of
its degradation products.
3.2. TLC-densitometric assay
3.2.1. Optimization and system suitability
Various developing systems of different compositions were
tried such as chloroform–methanol (1:1 v/v), chloroform–
ethanol (3:7 v/v), toluene–methanol (6:4 v/v), diethyl ether–
acetonitrile (8:2 v/v) and chloroform–isobutyl alcohol
(50:50 v/v).5 The results were evaluated with respect to the
efﬁciency of separation and the shape of separated bands.
Optimum resolution was obtained using chloroform: metha-
nol: glacial acetic acid (100:5:2 v/v/v) as shown in Fig. 3.
The Rf values for RIVA, D1 and D2 were 0.65, 0.33 and
0.87, respectively as shown in (Fig. 3). Analysis was carried
out using various band dimensions, scanning wavelengths
and slit dimensions. Sharp and symmetrical peaks were
obtained using a band width of 6 mm, inter-space between
bands of 5 mm and 249 nm as the scanning wavelength. Sys-
tem suitability parameters were calculated according to USP
guidelines27 in order to verify the separation efﬁciency
(Table 1).
Figure 2 HPLC analysis results showing (a) typical chromatogram for Rivaroxaban standard solution and the pattern of degradation
under (b) acid-catalyzed hydrolysis and (c) base-catalyzed hydrolysis.
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A set of RIVA standard solutions was analyzed as described
over a concentration range 0.40–12.00 lg/band. The
calibration curve was constructed and the regression andvalidation parameters were computed (Table 2). The
speciﬁcity of the assay was demonstrated through the ability
of the assay to determine RIVA in the presence of its
degradates.
Table 1 System suitability parameters of the proposed HPLC and TLC-densitometric assays.
Parameter HPLC Assay TLC-densitometry assay Reference value27
D2 RIVA D1 D2 RIVA D1
Resolution (Rs) 2.5 3.2 2.0 1.8 2.8 3.7 >1.5
Selectivity (a) 1.09 1.18 1.35 1.10 1.26 1.10 >1.0
Tailing factor (T) 1.12 1.08 1.20 1.01 0.94 1.11 About 1
Capacity factor (k0) 1.8 2.6 4.2 2.2 2.6 3.4 1–10
Number of theoretical plates (N) 2870 4336 6210 3428 3549 4396 Increase with eﬃciency of separation
Height equivalent to
theoretical plate (HETP)
1.89 · 103 1.1 · 103 1.89 · 103 1.26 · 103 2.10 · 103 1.21 · 103 The smaller the value the higher
the column eﬃciency
Table 2 A summary of validation and regression equation parameters of the HPLC and TLC-densitometric assays for the analysis of
Rivaroxaban.
Parameter HPLC assay TLC-densitometric assay
Range 5.00–50.00 lg/mL 0.40–12.00 lg/band
Linearity
Regression equation Y= 31672X+ 21,971 y= 122.6·3 + 1275·2 + 1735·+ 1546
Correlation coeﬃcient (R2) 0.999 0.997
Accuracya (mean ± RSD) 101.35 ± 0.90 99.58 ± 1.09
Precision
Repeatabilityb (RSD) 98.96 ± 0.51 101.78 ± 0.21
Intermediate precisionc (RSD) 99.74 ± 1.01 100.99 ± 1.53
Limit of detection (LOD) 2.50 lg/mL 0.20 lg/band
Limit of quantiﬁcation (LOQ) 5.00 lg/mL 0.40 lg/band
a Average percentage recovery of six determinations.
b The intra-day, average of three determinations repeated within the same day.
c The inter-day, average of three determinations repeated over three different.
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Stability testing of new drug substances requires that stress
degradation studies should be performed in order to establish
the inherent stability characteristics of active pharmaceutical
ingredients. This is particularly important with active pharma-
ceutical ingredients that require accurate dosing such as RIVA.
Such stability-indicating procedures should be validated to
pharmaceutical industry standards in order to ensure reliable
analysis results.28 Moreover, a validated stability-indicating
analysis protocol is an indispensable tool during the early
stages of pre-formulation studies of generic products. It
ensures the stability of the active ingredient during various
stages of formulation, production and storage. Well-designed
analysis protocols help prevent access of sub-standard medi-
cines into local markets.3.3.1. Degradation behavior
Results of the HPLC and TLC-densitometric assays of RIVA
degraded samples revealed that it was stable towards oxidative
(Fig. S4), photolytic (Fig. S5) and thermal stress conditions
(Fig. S6). This was demonstrated through comparison of the
chromatograms and peak areas obtained after applying the
indicated stress conditions to that of an equivalent control
sample. On the other hand, RIVA was found susceptible to
hydrolysis as shown in Fig. 2 and Fig. 3. Degraded samples
were analyzed using TLC and bands corresponding todegradation products were scratched, extracted using acetoni-
trile then analyzed using LC/MS/MS in order to reveal the
identity of each degradation product (Fig. S1). Using TLC
for preparation and isolation of the degradation products pre-
sents a simple and economic approach when compared to
semi-preparative HPLC that has been previously reported.16
Such approach requires sophisticated equipment, expensive
columns and large volumes of mobile phase. Results revealed
two bands corresponding to the major degradation products;
D1, m/z 454 and D2, m/z 410. The proposed degradation
mechanism and structures of degradation products were
shown in Figs. S1 and S2. Extracted degradates were further
investigated via analysis using HPLC-DAD in order to con-
ﬁrm the order of elution and peak purity. It should be noted
that peaks of relatively small intensity were detected at the
retention time of 1–1.5 min in Fig. 2B–C. Such peaks were
checked using the spectral function of the DAD and no spectra
were detected. This indicated that such peaks were not degra-
dation products but could be impurities in the sodium hydrox-
ide and the hydrochloric acid used.
These results were partially in agreement with the recently
reported pattern of degradation obtained using higher strength
hydrochloric acid and sodium hydroxide (1.0 N) presented by
Ramisetti et al.16 However, the third degradation product
claimed by the authors of that study was not detected in
the present study. Contrary to the results of base-catalyzed
hydrolysis presented by Bebawy et al.5 where two drgradation
products (m/z 251 and 144) were detected. This could be
Figure 3 TLC-densitometry analysis results showing (a) typical chromatogram for Rivaroxaban standard solution and the pattern of
degradation under (b) acid-catalyzed hydrolysis and (c) base-catalyzed hydrolysis.
Figure 4 Pseudo ﬁrst order plot showing the kinetics of base-catalyzed hydrolysis reaction using both HPLC and TLC-densitometric
assays.
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However, the authors did not show the degradation proﬁle at
acidic conditions.53.3.2. Kinetics of hydrolysis
RIVA was found to be highly liable to hydrolysis and almost
complete degradation was observed in the case of the base-cat-
alyzed hydrolysis. A linear relationship was obtained when ln
Ct/Co was plotted versus the reaction time which indicated ﬁrst
order kinetics (Fig. 4). The rate constant (KObs) and half-life
(t0.5) for acid- and base-catalyzed hydrolysis determined usingboth assays are summarized in Table 4. Results demonstrated
that the rate of hydrolysis was much slower in case of acidic
conditions when compared to that at basic conditions. Acid
and base-catalyzed hydrolysis reactions are bimolecular reac-
tions where one of the reactants (water) is present in large
excess. Since the change in water concentration is negligible,
equations describing ﬁrst order kinetics can be still applied.
However it is termed as a pseudo ﬁrst order rather than second
order reaction.21 It should be noted that the good correlation
coefﬁcient obtained along with the peak purity results con-
ﬁrmed the following: (i) mechanism of degradation of RIVA
is the same throughout the duration of experiment, and (ii)
Table 3 Analysis results of three Rivaroxaban tablet generic formulations in comparison to the Innovator product (Xarelto 10 mg
tablets).
Assay Innovator product E001 E002 E003
Reported method [12] 99.83 ± 0.37 100.58 ± 0.56 98.52 ± 0.76 99.36 ± 0.22
HPLC assay 99.29 ± 0.19 100.27 ± 1.2 98.76 ± 0.38 99.70 ± 0.91
TLC-Densitometric assay 100.38 ± 0.31 99.37 ± 0.84 100.27 ± 0.69 98.60 ± 1.02
Table 4 Summary of the kinetics parameters for the base and acid-catalyzed hydrolysis of Rivaroxaban using HPLC and TLC-
densitometric assays.
Base-catalyzed hydrolysis Acid-catalyzed hydrolysis
HPLC assay TLC-densitometric assay HPLC assay TLC-densitometric assay
Reaction rate constant (KObs, min
1) 0.0413 0.0356 0.0044 0.0045
Half-life (t0.5, min) 16.8 19.5 157.5 154.0
R2 0.998 0.999 0.962 0.966
60 M.A. Abdallah et al.contrary to previously published results16 only two major deg-
radation products were formed under the studied experimental
conditions.
3.4. Applications
3.4.1. Application to pharmaceutical formulations
The proposed analysis protocol was applied for the determina-
tion of RIVA in the innovator product. Satisfactory results
were obtained and were in agreement with the results of the
reported method,12 as shown in Table 3. However, it should
be noted that the reported method is not a stability-indicating
assay and cannot be applied for the analysis of RIVA in the
presence of its degradation products.
3.4.2. Application to preformulation studies
Preformulation studies are integral part in the development
and design of new pharmaceutical formulations. In vitro disso-
lution testing is ofﬁcial test of the pharmacopoeias for evalua-
tion of drug release from solid and semisolid dosage
formulations and is a prerequisite for correlation of in vitro
and in vivo studies. Dissolution testing is also a routinely used
tool in quality control to ensure batch to batch consistency. In
this study, the developed analysis protocol was employed for
evaluation of three generic tablet formulas of RIVA with
respect to content and in vitro dissolution pattern. The generic
formulas were prepared using different amounts of sodium
lauryl sulfate in order to enhance the dissolution and the
release pattern was investigated in comparison to the innova-
tor product. Results revealed no signiﬁcant difference with
respect to RIVA content between the innovator product and
all generic formulations (Table 3). However, the dissolution
pattern showed a clear dependence on the amount of the sur-
factant added (Fig. S7). Formula E003 was considered the
optimum formulation since it matched the dissolution pattern
of the innovator product. Results demonstrated also the ability
of the HPLC assay to determine minor differences in the disso-
lution pattern. Since a stability-indicating analysis protocol
has been employed in this study, it could be concluded that
RIVA is sufﬁciently stable in the dissolution medium through-
out the duration of study as shown in Fig. S8.4. Conclusion
In this study, the stability proﬁle of Rivaroxaban has been
investigated in detail. It was found stable towards oxidation,
photodegradation and thermal decomposition. On the other
hand, Rivaroxaban was found labile to base and acid-cat-
alyzed hydrolysis. The identity of Rivaroxaban degradation
products was revealed using LC/MS/MS and was in agreement
to the proposed theoretical route of degradation. The noted
pattern of degradation was compared to the previously
reported studies and differences were discussed. An orthogo-
nal, sensitive and simple stability-indicating analysis protocol,
RP-HPLC and NP-TLC densitometry was developed and val-
idated to pharmaceutical industry standards. The analysis pro-
tocol was successfully employed for the analysis of the
innovator product and during the preformulation studies of
three generic Rivaroxaban formulations.
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